JP2025063187A5 - - Google Patents
Info
- Publication number
- JP2025063187A5 JP2025063187A5 JP2025005276A JP2025005276A JP2025063187A5 JP 2025063187 A5 JP2025063187 A5 JP 2025063187A5 JP 2025005276 A JP2025005276 A JP 2025005276A JP 2025005276 A JP2025005276 A JP 2025005276A JP 2025063187 A5 JP2025063187 A5 JP 2025063187A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- disease
- immune
- vector
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163273216P | 2021-10-29 | 2021-10-29 | |
| US63/273,216 | 2021-10-29 | ||
| JP2022172479A JP7622019B2 (ja) | 2021-10-29 | 2022-10-27 | インターロイキン－３４を標的とする化合物及び方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022172479A Division JP7622019B2 (ja) | 2021-10-29 | 2022-10-27 | インターロイキン－３４を標的とする化合物及び方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025063187A JP2025063187A (ja) | 2025-04-15 |
| JP2025063187A5 true JP2025063187A5 (https=) | 2025-11-04 |
Family
ID=84367272
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022172479A Active JP7622019B2 (ja) | 2021-10-29 | 2022-10-27 | インターロイキン－３４を標的とする化合物及び方法 |
| JP2024066552A Pending JP2024091777A (ja) | 2021-10-29 | 2024-04-17 | インターロイキン－３４を標的とする化合物及び方法 |
| JP2025005276A Pending JP2025063187A (ja) | 2021-10-29 | 2025-01-15 | インターロイキン－３４を標的とする化合物及び方法 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022172479A Active JP7622019B2 (ja) | 2021-10-29 | 2022-10-27 | インターロイキン－３４を標的とする化合物及び方法 |
| JP2024066552A Pending JP2024091777A (ja) | 2021-10-29 | 2024-04-17 | インターロイキン－３４を標的とする化合物及び方法 |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US11976114B2 (https=) |
| EP (1) | EP4423127A1 (https=) |
| JP (3) | JP7622019B2 (https=) |
| KR (1) | KR20240099349A (https=) |
| CN (1) | CN118475610A (https=) |
| AR (1) | AR127484A1 (https=) |
| AU (1) | AU2022376940A1 (https=) |
| CA (1) | CA3236555A1 (https=) |
| CL (1) | CL2024001303A1 (https=) |
| CO (1) | CO2024005417A2 (https=) |
| CR (1) | CR20240170A (https=) |
| DO (1) | DOP2024000076A (https=) |
| EC (1) | ECSP24032906A (https=) |
| IL (1) | IL312380A (https=) |
| JO (1) | JOP20240103A1 (https=) |
| MX (1) | MX2024005153A (https=) |
| PE (1) | PE20241471A1 (https=) |
| TW (1) | TW202336034A (https=) |
| WO (1) | WO2023076995A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023150483A1 (en) * | 2022-02-03 | 2023-08-10 | Eli Lilly And Company | Regional tau imaging for diagnosing and treating alzheimer's disease |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2320942B1 (en) | 2008-07-21 | 2018-03-14 | Probiodrug AG | Diagnostic antibody assay |
| US8795664B2 (en) | 2010-06-04 | 2014-08-05 | Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin | Monoclonal antibodies targeting amyloid beta oligomers |
| WO2012019061A2 (en) * | 2010-08-05 | 2012-02-09 | Stem Centrx, Inc. | Novel effectors and methods of use |
| PT3042917T (pt) | 2010-08-12 | 2018-05-02 | Lilly Co Eli | Anticorpos do péptido beta amilóide anti-n3pglu e seus usos |
| WO2012136552A1 (en) | 2011-04-08 | 2012-10-11 | H. Lundbeck A/S | ANTIBODIES SPECIFIC TO PYROGLUTAMATED Αβ |
| US9161968B2 (en) | 2011-04-08 | 2015-10-20 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of neuroprotection involving macrophage colony stimulating factor receptor agonists |
| RU2014136332A (ru) | 2012-02-06 | 2016-03-27 | Дженентек, Инк. | Композиции и способы применения ингибиторов csf1r |
| MX2017001293A (es) | 2014-07-28 | 2017-05-23 | Nogra Pharma Ltd | Metodos y composiciones para diagnosticar y tratar trastornos inflamatorios del intestino. |
| US10703813B2 (en) | 2014-12-19 | 2020-07-07 | Universite De Nantes | Anti IL-34 antibodies |
| PL3988117T3 (pl) * | 2015-04-13 | 2025-03-10 | Pfizer Inc. | Przeciwciała terapeutyczne i ich zastosowania |
| EP3302552A1 (en) | 2015-06-02 | 2018-04-11 | H. Hoffnabb-La Roche Ag | Compositions and methods for using anti-il-34 antibodies to treat neurological diseases |
| JOP20170004B1 (ar) | 2016-01-15 | 2022-09-15 | Lilly Co Eli | الأجسام المضادة لببتيد بيتا النشوي مضاد N3pGlu واستخداماته |
| TWI798751B (zh) * | 2016-07-01 | 2023-04-11 | 美商美國禮來大藥廠 | 抗－N3pGlu類澱粉β肽抗體及其用途 |
| EP3496750A2 (en) | 2016-08-09 | 2019-06-19 | Eli Lilly and Company | Combination therapy |
| TWI705975B (zh) | 2017-04-20 | 2020-10-01 | 美商美國禮來大藥廠 | 抗－N3pGlu類澱粉β肽抗體及其用途 |
| WO2019169291A1 (en) | 2018-03-02 | 2019-09-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Use of il-34 to treat retinal inflammation and neurodegeneration |
| MX2021014473A (es) | 2019-05-31 | 2022-01-06 | Lilly Co Eli | Compuestos y metodos dirigidos a la tau humana. |
| AR121898A1 (es) | 2020-04-30 | 2022-07-20 | Lilly Co Eli | Compuestos y métodos dirigidos a interleucina-34 |
-
2022
- 2022-10-27 AR ARP220102931A patent/AR127484A1/es unknown
- 2022-10-27 WO PCT/US2022/078776 patent/WO2023076995A1/en not_active Ceased
- 2022-10-27 CR CR20240170A patent/CR20240170A/es unknown
- 2022-10-27 IL IL312380A patent/IL312380A/en unknown
- 2022-10-27 EP EP22814582.7A patent/EP4423127A1/en active Pending
- 2022-10-27 US US18/050,227 patent/US11976114B2/en active Active
- 2022-10-27 CN CN202280086946.7A patent/CN118475610A/zh active Pending
- 2022-10-27 CA CA3236555A patent/CA3236555A1/en active Pending
- 2022-10-27 JP JP2022172479A patent/JP7622019B2/ja active Active
- 2022-10-27 KR KR1020247017337A patent/KR20240099349A/ko active Pending
- 2022-10-27 TW TW111140796A patent/TW202336034A/zh unknown
- 2022-10-27 PE PE2024000938A patent/PE20241471A1/es unknown
- 2022-10-27 AU AU2022376940A patent/AU2022376940A1/en active Pending
- 2022-10-27 MX MX2024005153A patent/MX2024005153A/es unknown
-
2024
- 2024-04-05 US US18/628,082 patent/US20240309082A1/en active Pending
- 2024-04-17 JP JP2024066552A patent/JP2024091777A/ja active Pending
- 2024-04-26 CL CL2024001303A patent/CL2024001303A1/es unknown
- 2024-04-26 CO CONC2024/0005417A patent/CO2024005417A2/es unknown
- 2024-04-26 DO DO2024000076A patent/DOP2024000076A/es unknown
- 2024-04-29 EC ECSENADI202432906A patent/ECSP24032906A/es unknown
- 2024-04-29 JO JOJO/P/2024/0103A patent/JOP20240103A1/ar unknown
-
2025
- 2025-01-15 JP JP2025005276A patent/JP2025063187A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022002524A5 (https=) | ||
| JP2024109678A5 (https=) | ||
| CN109937212B (zh) | B7-h3抗体、其抗原结合片段及其医药用途 | |
| JP2022191383A5 (https=) | ||
| JP2023116770A5 (https=) | ||
| JP2023002562A5 (https=) | ||
| JP2021526022A5 (https=) | ||
| JP2025067915A5 (https=) | ||
| JP2011207882A5 (https=) | ||
| RU2007118670A (ru) | Ангиопоэтин-2-специфические связывающие агенты | |
| JP2024024114A5 (https=) | ||
| US20250042991A1 (en) | Leptin antibodies and method of reducing leptin | |
| JP2023510787A (ja) | 抗ａｎｇｐｔｌ３抗体及びその応用 | |
| JP2025063187A5 (https=) | ||
| CN114591434A (zh) | 抗Siglec15抗体及其制备方法和用途 | |
| CN113840836B (zh) | 抗结缔组织生长因子抗体及其应用 | |
| JP2025087764A5 (https=) | ||
| WO2019230869A1 (ja) | 抗ヒトｔｌｒ７抗体 | |
| CN114594272B (zh) | 用于检测β-淀粉样蛋白的产品和方法 | |
| CN114578066B (zh) | 检测β-淀粉样蛋白的产品和方法 | |
| CN112480259A (zh) | 抗tnfr2抗体及其用途 | |
| EP2497782A1 (en) | Anti oligomer antibodies and uses thereof | |
| JP2024091777A5 (https=) | ||
| IL312380A (en) | Compounds and methods targeting interleukin-34 | |
| CN114605532B (zh) | 抗β-淀粉样蛋白抗体及其用途 |